| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Elena Verzoni | Q39606195 |
| Giuseppe Procopio | Q39606238 | ||
| Paolo Grassi | Q42343466 | ||
| Raffaele Ratta | Q56697492 | ||
| Filippo de Braud | Q37837953 | ||
| P2093 | author name string | Alessia Mennitto | |
| P2860 | cites work | The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance | Q38175267 |
| A phase I study of cabozantinib (XL184) in patients with renal cell cancer. | Q38430335 | ||
| Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions | Q39085630 | ||
| Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth | Q39472261 | ||
| Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma | Q41316099 | ||
| HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors | Q42819341 | ||
| MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array | Q46111473 | ||
| Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. | Q53494761 | ||
| MET as a target in papillary renal cell carcinoma | Q87843055 | ||
| Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis | Q24608039 | ||
| c-Met as a Target for Personalized Therapy | Q26775483 | ||
| Cancer treatment and survivorship statistics, 2012 | Q27020961 | ||
| Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma | Q27851979 | ||
| Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial | Q29618031 | ||
| Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial | Q33946929 | ||
| The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells | Q33959078 | ||
| High expression of the Met receptor in prostate cancer metastasis to bone | Q34163761 | ||
| Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. | Q34217927 | ||
| Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma | Q34495684 | ||
| Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models | Q34978329 | ||
| MET and VEGF: synergistic targets in castration-resistant prostate cancer | Q35575488 | ||
| c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma | Q36551653 | ||
| Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer | Q36822111 | ||
| Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen | Q36954859 | ||
| Targeting the Met signaling pathway in renal cancer. | Q37331862 | ||
| Novel therapeutic inhibitors of the c-Met signaling pathway in cancer | Q37422804 | ||
| Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. | Q37430185 | ||
| Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy | Q37989752 | ||
| Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma | Q38122564 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | renal cell carcinoma | Q1164529 |
| antineoplastic | Q2853144 | ||
| drug design | Q2991682 | ||
| anilides | Q4066270 | ||
| pyridine | Q47317020 | ||
| kidney neoplasm | Q13641482 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 2167-72 | |
| P577 | publication date | 2016-07-05 | |
| P1433 | published in | Drug Design, Development and Therapy | Q2566724 |
| P1476 | title | Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy | |
| P478 | volume | 10 |
| Q47143379 | A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma |
| Q39026733 | Cabozantinib: A Review in Advanced Renal Cell Carcinoma |
| Q47283034 | Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma |
| Q49887919 | Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors |
| Q41346916 | Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma |
| Q39092934 | Treatment options in advanced renal cell carcinoma after first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors |
Search more.